PBE stock forecast, quote, news & analysis

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI).

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

The average market capitalization across the Invesco Biotechnology & Genome ETF ETF is 20.49B. The market cap for tickers in the group ranges from 625.86M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is EYPT at 625.86M.

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was -8%. For the same ETF, the average monthly price growth was -5%, and the average quarterly price growth was 2%. TGTX experienced the highest price growth at 3%, while HALO experienced the biggest fall at -25%.

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 57%. For the same stocks of the ETF, the average monthly volume growth was 120% and the average quarterly volume growth was 101%